Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Prostate cancer drugs may shrink breast tumours

  • Comment

Breast cancer treatment could be transformed by using men’s prostate cancer drugs to shrink tumours, researchers have claimed.

The early stages of a new study suggest that prostate drugs could treat certain forms of breast cancer by blocking the tumour-fuelling effects of testosterone.

More than a fifth of breast tumours are not stimulated by oestrogen, making them hard to treat because they do not respond to therapies such as tamoxifen.

Prostate drugs that work in a similar way to tamoxifen could be used to treat these “oestrogen negative” tumours, according to the study.

Laboratory tests showed that it might be possible to combat the tumours by using prostate hormone therapy to block a testosterone pathway that switches on genes normally activated by oestrogen.

Lead researcher Dr Ian Mills, from Cancer Research UK’s Cambridge Research Institute, said: “This important discovery suggests that patients with a type of oestrogen-receptor-negative breast cancer may potentially benefit from therapies given to prostate cancer patients, which could transform treatment for this patient group in the future.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs